Effectiveness and safety of ceftazidime-avibactam in Chinese patients with hospital-acquired pneumonia, including ventilator-associated pneumonia: A Phase 4, multi-centre, open-label study
Ceftazidime-avibactam was effective in Chinese patients with HAP/VAP, and results were consistent with the Phase 3 REPROVE study. These findings support the use of ceftazidime-avibactam as a potential treatment option in Chinese adults with HAP/VAP.
Authors
- Liangfa Tang
- Fanglei Liu (ORCID: https://orcid.org/0009-0009-4162-207X)
- Yunsong Yu (ORCID: https://orcid.org/0000-0003-2903-918X)
- Rienk Pypstra
- Zuke Xiao
- Yingyuan Zhang (ORCID: https://orcid.org/0000-0001-9564-2353)
- Haihui Huang (ORCID: https://orcid.org/0000-0002-6546-969X)
- Hua Qiao (ORCID: https://orcid.org/0000-0002-4543-4908)
- Yuting Mu
- Jinyi Yuan (ORCID: https://orcid.org/0009-0005-5424-4662)
- Aimin Li (ORCID: https://orcid.org/0000-0003-0918-614X)
- Bin Liu (ORCID: https://orcid.org/0000-0003-1691-8126)
- Panpan Wang (ORCID: https://orcid.org/0000-0002-0218-6019)
- Xiaoyue Chang
- Huiqing Zeng
- Ning Xu (ORCID: https://orcid.org/0000-0003-1590-9359)
- Paurus Irani
- Junchao Lu
- Fei Guo (ORCID: https://orcid.org/0000-0003-2911-7643)
Institutions
- Pfizer (United States) (US)
- Pfizer (United Kingdom) (GB)
- Fudan University (CN)
- Sir Run Run Shaw Hospital (CN)
- Fuyang City People's Hospital (CN)
- Jiangyin People's Hospital (CN)
- Jiangxi Provincial People's Hospital (CN)
- Zhongshan Hospital of Xiamen University (CN)
- Baotou Central Hospital (CN)
- The First People’s Hospital of Lianyungang (CN)
- Huizhou Central People's Hospital (CN)
- The First People's Hospital of Guiyang (CN)
- Pfizer (China) (CN)
- Huashan Hospital (CN)
- Fuyang Second People's Hospital (CN)
Publication Details
- Journal
- Journal of Global Antimicrobial Resistance
- Published
- 2025-03-08
- DOI
- https://doi.org/10.1016/j.jgar.2025.03.001
- Primary Topic
- Antibiotic Resistance in Bacteria
- Type
- article
- Field-Weighted Citation Impact
- 0.00